Latest News and Press Releases
Want to stay updated on the latest news?
-
LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
-
LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
-
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
-
LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
-
On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry...
-
LONDON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
-
Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief...
-
Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc...
-
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected...
-
LONDON, May 12, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV gene...